Stock HEAL PT MEDIKALOKA HERMINA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Medikaloka Hermina Tbk

Equities

HEAL

ID1000143100

Healthcare Facilities & Services

End-of-day quote INDONESIA S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1,090 IDR +0.46% Intraday chart for PT Medikaloka Hermina Tbk -6.03% -26.85%
Mar. 28 PT Medikaloka Hermina Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 PT Medikaloka Hermina Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,643,340 10,459,390 15,701,180 22,417,924 21,692,778 16,117,150 - -
Enterprise Value (EV) 2 11,345 11,152 16,078 23,380 23,098 17,197 16,871 17,096
P/E ratio 42.3 x 22.6 x 15.9 x 75.4 x 50.1 x 28.5 x 23.1 x 21 x
Yield - 0.71% 0.56% 0.57% - 0.98% 1.22% 1.4%
Capitalization / Revenue 2.93 x 2.37 x 2.7 x 4.57 x 3.75 x 2.45 x 2.23 x 2 x
EV / Revenue 3.12 x 2.53 x 2.76 x 4.77 x 3.99 x 2.62 x 2.33 x 2.12 x
EV / EBITDA 13.1 x 8.04 x 7.26 x 20.5 x 15.8 x 9.3 x 8.11 x 7.03 x
EV / FCF -3,374 x 23.9 x 25 x -89.5 x -85 x -273 x 36.9 x 24.7 x
FCF Yield -0.03% 4.19% 4% -1.12% -1.18% -0.37% 2.71% 4.05%
Price to Book 4.96 x 4.09 x 4.87 x 6.52 x 5.61 x 3.77 x 3.21 x 3.03 x
Nbr of stocks (in thousands) 14,865,000 14,815,000 14,674,000 14,463,176 14,558,911 14,786,376 - -
Reference price 3 716.0 706.0 1,070 1,550 1,490 1,090 1,090 1,090
Announcement Date 4/5/20 5/17/21 3/31/22 3/31/23 3/28/24 - - -
1IDR in Million2IDR in Billions3IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,631 4,416 5,820 4,902 5,784 6,567 7,230 8,074
EBITDA 1 866.6 1,387 2,213 1,142 1,464 1,849 2,079 2,432
EBIT 1 583.3 1,042 1,778 587.4 818 973.2 1,208 1,345
Operating Margin 16.06% 23.59% 30.55% 11.98% 14.14% 14.82% 16.71% 16.65%
Earnings before Tax (EBT) 1 505.5 946 1,658 480.1 710.4 917.2 1,080 1,207
Net income 1 255.4 473.2 1,003 298.6 437.3 564.9 694.8 751
Net margin 7.03% 10.72% 17.24% 6.09% 7.56% 8.6% 9.61% 9.3%
EPS 2 16.92 31.18 67.28 20.57 29.73 38.22 47.13 52.00
Free Cash Flow 3 -3,362 466,723 642,792 -261,272 -271,707 -63,000 456,604 693,000
FCF margin -92.59% 10,568.81% 11,044.3% -5,330.11% -4,697.49% -959.32% 6,315.69% 8,583.37%
FCF Conversion (EBITDA) - 33,649.82% 29,040.59% - - - 21,961.81% 28,491.83%
FCF Conversion (Net income) - 98,626.65% 64,078.89% - - - 65,717.27% 92,276.96%
Dividend per Share 2 - 5.000 6.000 8.874 - 10.70 13.32 15.28
Announcement Date 4/5/20 5/17/21 3/31/22 3/31/23 3/28/24 - - -
1IDR in Billions2IDR3IDR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2023 Q1 2023 Q3 2023 Q4
Net sales 1 1,529 1,193 - 1,538 1,554
EBITDA 546.7 469.1 - - -
EBIT 1 402.6 358.7 - - 178.6
Operating Margin 26.33% 30.07% - - 11.49%
Earnings before Tax (EBT) 1 374.9 327.7 - - 150.2
Net income 1 228.5 230 108.9 - 88.51
Net margin 14.95% 19.28% - - 5.69%
EPS - - 7.490 - -
Dividend per Share - - - - -
Announcement Date 11/5/21 3/31/22 4/25/23 10/18/23 3/28/24
1IDR in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 701 692 376 962 1,405 1,080 753 979
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.8094 x 0.4992 x 0.17 x 0.8426 x 0.9599 x 0.584 x 0.3624 x 0.4024 x
Free Cash Flow 2 -3,362 466,723 642,792 -261,272 -271,707 -63,000 456,604 693,000
ROE (net income / shareholders' equity) 12.7% 20.1% 34.5% 8.1% 12% 13.5% 15.3% 15.1%
ROA (Net income/ Total Assets) 5.54% 8.3% 14.4% 5% 5.34% 7.62% 8% 6.6%
Assets 1 4,610 5,702 6,971 5,972 8,197 7,411 8,683 11,379
Book Value Per Share 3 144.0 172.0 220.0 238.0 266.0 289.0 339.0 359.0
Cash Flow per Share 3 37.90 74.20 125.0 59.80 89.70 109.0 107.0 136.0
Capex 1 576 890 1,214 1,129 1,591 1,013 953 -
Capex / Sales 15.86% 20.15% 20.85% 23.03% 27.51% 15.43% 13.18% -
Announcement Date 4/5/20 5/17/21 3/31/22 3/31/23 3/28/24 - - -
1IDR in Billions2IDR in Million3IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PT Medikaloka Hermina Tbk

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1,090 IDR
Average target price
1,680 IDR
Spread / Average Target
+54.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
PT MEDIKALOKA HERMINA TBK Stock PT Medikaloka Hermina Tbk
-26.85% 993M
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. HEAL Stock
  4. Financials PT Medikaloka Hermina Tbk